SCHEMBL1997243

SCHEMBL1997243

CC(C)CN1C(=O)CN(Cc2ccc(-c3ccc(F)c(CN4CCCCC4)c3)cc2)C1=O

nearest known ligand 0.44

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
HRH3 Q9Y5N1 5/20 0.44
NMT1 P30419 1/20 0.42
ALDH1A1 P00352 2/20 0.40
HTT P42858 1/20 0.40
ENPP2 Q13822 3/20 0.39
HRH4 Q9H3N8 1/20 0.39
KDM4E B2RXH2 2/20 0.37
SMN1; SMN2 Q16637 1/20 0.37
HDAC6 Q9UBN7 2/20 0.36
HDAC1 Q13547 1/20 0.36
HDAC2 Q92769 1/20 0.36
HDAC8 Q9BY41 1/20 0.36
CYP2D6 P10635 1/20 0.36
CYP2C19 P33261 1/20 0.36
MCHR1 Q99705 2/20 0.36
MTNR1B P49286 1/20 0.36
HTR2C P28335 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1995456 0.90 LRRK2 (0.41) HRH3NMT1ENPP2HDAC6HDAC1
SCHEMBL2001890 0.90 KMT2A (0.37) HRH3NMT1ENPP2HDAC6HDAC1
SCHEMBL1997193 0.84 HRH3 (0.46) HRH3ALDH1A1HTTENPP2HRH4
SCHEMBL1998795 0.84 CYP2D6 (0.49) HRH3NMT1ENPP2HRH4HDAC6
SCHEMBL2001267 0.83 CHKA (0.41) HRH3ALDH1A1ENPP2HRH4HDAC6
SCHEMBL1997569 0.78 CYP2D6 (0.49) HRH3ALDH1A1HTTENPP2HRH4
SCHEMBL2000696 0.77 WDR5 (0.41) HRH3
SCHEMBL840172 0.76 HRH3 (0.41) HRH3ENPP2HRH4HDAC6CYP2D6
SCHEMBL1994800 0.74 HRH3 (0.41) HRH3ALDH1A1ENPP2HRH4KDM4E
SCHEMBL1998874 0.74 MCHR1 (0.35) HRH3ALDH1A1ENPP2HDAC6HDAC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7960560-B2 1-(biphenyl-4-ylmethyl)imidazolidine-2,4-dione N.V. ORGANON (NL) 2011-06-14 US claimed
US-20100144723-A1 1-(BIPHENYL-4-YLMETHYL)IMIDAZOLIDINE-2,4-DIONE N. V. ORGANON 2010-06-10 US claimed
EP-2373627-A1 1- (BIPHENYL-4-YLMETHYL) IMIDAZOLIDINE-2, 4-DIONE DERIVATIVES AND THEIR USE AS CB2 RECEPTOR AGONISTS N.V. Organon (NL) 2011-10-12 EP disclosed
US-7960560-B2 1-(biphenyl-4-ylmethyl)imidazolidine-2,4-dione N.V. ORGANON (NL) 2011-06-14 US disclosed
US-20100144723-A1 1-(BIPHENYL-4-YLMETHYL)IMIDAZOLIDINE-2,4-DIONE N. V. ORGANON 2010-06-10 US disclosed
WO-2010063721-A1 1- (BIPHENYL-4-YLMETHYL) IMIDAZOLIDINE-2, 4-DIONE DERIVATIVES AND THEIR USE AS CB2 RECEPTOR AGONISTS N.V. ORGANON (NL) 2010-06-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100144723-A1 1-(BIPHENYL-4-YLMETHYL)IMIDAZOLIDINE-2,4-DIONE OPRM1, OR10J3, OPRD1 HRH3 32/4885NMT1 4180/4885ALDH1A1 3054/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.